<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347872">
  <stage>Registered</stage>
  <submitdate>17/12/2011</submitdate>
  <approvaldate>20/01/2012</approvaldate>
  <actrnumber>ACTRN12612000101886</actrnumber>
  <trial_identification>
    <studytitle>Evaluation of the Radioprotective Effect of Famotidine Against Radiotherapy- induced Acute Toxicity in Patients with Prostate Cancer</studytitle>
    <scientifictitle>A Randomized controled trial of Famotidine as a Radioprotector agent versus Placebo before External Beam Radiotherapy in Patients with Prostate Cancer to Reduce Radiation- induced Acute Bowel &amp; Urinary Toxicity using RTOG Criteria </scientifictitle>
    <utrn>U1111-1126-4224</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate Cancer</healthcondition>
    <healthcondition>Bowel toxicity</healthcondition>
    <healthcondition>Urinary toxicity</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Normal oral and gastrointestinal development and function</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Normal development and function of male and female renal and urogenital system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral Famotidine 40mg is administrated daily for 2 months twice per day before 2 months Radiotherapy: Once 4 hours before and the other 3 hours before daily Radiotherapy. A Physician determines Bowel &amp; Urinary Toxicities Grade for the patients every week during the treatment by interviewing and blood cell counts are collected biweekly. </interventions>
    <comparator>Placebo tablets exactly are as same as famotidine tablets in all properties just with no active ingredient. The administration of placebo and assessment of Radiotherapy-Induced Toxicity Grade for control Group are as similar as Famotidine Group.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Gastrointestinal Acute Toxicity as assessed using the RTOG Grading Criteria</outcome>
      <timepoint>every week during the treatment and one month after end of the treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Genitourinary Acute Toxicity as assessed using the RTOG Grading Criteria</outcome>
      <timepoint>every week during the treatment and one month after end of the treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Heme Acute Toxicity as assessed using the RTOG Grading Criteria</outcome>
      <timepoint>every two weeks during the treatment and one month after end of the treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with Prostate Cancer Candidate for External Beam Radiotherapy</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with Metastatic Prostate Cancer, Patients with Kidney &amp; Liver dysfunction, Patients who receive any H2 Histamine receptor antagonist simultaneously, Patients with Allergic reaction in consequence of Famotidine Administration.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>An off-site person was employed for allocating Famotidine or placebo to Group A or B. Thus every participant who is enrolled in the study receives Famotidine or placebo according to this concealed and randomized schedule.</concealment>
    <sequence>The PASS11 Computer Software was used to generate a randomization list. 36 Participants are allocated in 2 Groups: Group A &amp; Group B </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>18/04/2012</anticipatedstartdate>
    <actualstartdate>17/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>11/02/2013</actualenddate>
    <samplesize>36</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Tehran</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>School of Paramedical Sciences, Shahid Beheshti Medical University,</primarysponsorname>
    <primarysponsoraddress>Darband Street, Tajrish Square, Tehran, I.R Iran.</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>School of Paramedical Sciences, Shahid Beheshti Medical University,</fundingname>
      <fundingaddress>Darband Street, Tajrish Square, Tehran, I.R Iran.</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Abolfazl Razzaghdoust</sponsorname>
      <sponsoraddress>School of Paramedical Sciences, Shahid Beheshti Medical University, Tehran, I.R Iran.</sponsoraddress>
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr. Hossein Mozdarani</othercollaboratorname>
      <othercollaboratoraddress>School of Medical Sciences, Tarbiat
Modarres University, P.O.Box: 14115-111, Tehran, I.R Iran.</othercollaboratoraddress>
      <othercollaboratorcountry>Iran, Islamic Republic Of</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr.Bahram Mofid</othercollaboratorname>
      <othercollaboratoraddress>Shohadaye Tajrish Hospital, Tajrish Sq, Tehran, I.R Iran.</othercollaboratoraddress>
      <othercollaboratorcountry>Iran, Islamic Republic Of</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr.Seyed Mahmoudreza Aghamiri</othercollaboratorname>
      <othercollaboratoraddress>Shahid Beheshti University
Velenjak avenue, Parvaneh street, Tehran, Iran</othercollaboratoraddress>
      <othercollaboratorcountry>Iran, Islamic Republic Of</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Amirhossein Heidari</othercollaboratorname>
      <othercollaboratoraddress>Babol paramedical University, ganjafruz street, Babol,Iran</othercollaboratoraddress>
      <othercollaboratorcountry>Iran, Islamic Republic Of</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>There is some animal and human cell evidences to support a Radioprotectory role for Famotidin. In the last few years there has been increasing interest to find a suitable Radioprotector agent for Radotherapy. The aims of this trial are to
1) determine the efficacy of Famotidine to prevent of bowel Radiation-Induced Toxicity
2) determine the efficacy of Famotidine to prevent of Urinary Radiation-Induced Toxicity
3) determine the efficacy of Famotidine to prevent of Immune system Radiation-Induced Toxicity</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Shahid Beheshti Medical University</ethicname>
      <ethicaddress>Velenjak avenue, Parvaneh street, Tehran, Iran</ethicaddress>
      <ethicapprovaldate>10/01/2012</ethicapprovaldate>
      <hrec>109</hrec>
      <ethicsubmitdate>20/11/2011</ethicsubmitdate>
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Hossein Mozdarani</name>
      <address>School of Medical Sciences, Tarbiat Modarres University, P.O.Box: 14115-111, Tehran, I.R Iran.</address>
      <phone>+98 21 82883830 ( for Tehran, I.R Iran)</phone>
      <fax>+98 21 82884555 ( for Tehran, I.R Iran)</fax>
      <email>mozdarah@modares.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Abolfazl Razzaghdoust</name>
      <address>School of Paramedical Sciences, Shahid Beheshti Medical University, Tehran, I.R Iran.</address>
      <phone>+98 919 2011639 ( for Tehran, I.R Iran)</phone>
      <fax>+98 21 88825904 ( for Tehran, I.R Iran)</fax>
      <email>Razzaghdoust@sbmu.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Abolfazl Razzaghdoust</name>
      <address>School of Paramedical Sciences, Shahid Beheshti Medical University, Tehran, I.R Iran.</address>
      <phone>+98 21 88825904 ( for Tehran, I.R Iran)</phone>
      <fax>+98 21 88825904 ( for Tehran, I.R Iran)</fax>
      <email>Razzaghdoust@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Abolfazl Razzaghdoust</name>
      <address>School of Paramedical Sciences, Shahid Beheshti Medical University, Tehran, I.R Iran. postal code:1971653313</address>
      <phone>+98 919 2011639  </phone>
      <fax>+98 21 88825904  </fax>
      <email>Razzaghdoust@sbmu.ac.ir   </email>
      <country>Iran, Islamic Republic Of</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>